Identifying Blood-Based Markers for Optimized Bipolar Androgen Therapy in mCRPC

Samuel Denmeade, MD, of Johns Hopkins University School of Medicine, highlights his research on blood-based markers of differential efficacy of bipolar androgen therapy and enzalutamide in the randomized TRANSFORMER trial.

This research was presented as a late-breaking abstract at the 2024 American Society of Clinical Oncology Annual Meeting.